Real TAKHZYRO patient
REIMAGINE YOUR LIFE WITH HAE
TAKHZYRO is a first-of-its-kind medicine used to prevent
attacks of hereditary angioedema (HAE) in people 12 years of
age and older.
Reimagine your life with fewer attacks
Fewer attacks or zero attacks for period of time in the clinical studies
People taking TAKHZYRO in 2 clinical studies, a 6.5-month
study and a 2.5-year, open-label extension study, had HAE
attacks less often. Some people in the studies had
zero attacks. Want to see the details?
In a 6.5-month clinical study of 125 people with HAE 12 years of age and older, TAKHZYRO significantly reduced the number of monthly attacks, compared with placebo. People taking TAKHZYRO also had fewer moderate or severe attacks and fewer attacks requiring acute treatment, compared with placebo. And according to a supportive analysis, there were people taking TAKHZYRO who had zero attacks during the entire clinical trial. In the 2.5-year, long-term, open-label extension study with 212 people with HAE, people taking TAKHZYRO had similar results compared with baseline. Baseline means a person's attack rate before beginning treatment in either the 6.5-month clinical trial or the long-term, open-label study. Long term safety of TAKHZYRO was the primary endpoint in the open-label extension study.
TAKHZYRO may cause serious side effects, including allergic reactions.
TAKHZYRO is a subcutaneous (under-the-skin)
injection you give yourself just once every 2 weeks
after being trained by a healthcare provider.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO. If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg every 4 weeks.
See what made patients
want to start TAKHZYRO
Ready to ask your doctor about TAKHZYRO?
Curious about what TAKHZYRO could do for you? Ask
your doctor. You can use our discussion guide to help
get the conversation started.
Personalized product support every step of the way
OnePath® helps people who have been prescribed TAKHZYRO per the approved indication get access to their medication.